1. Home
  2. PLBY vs SPRO Comparison

PLBY vs SPRO Comparison

Compare PLBY & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.59

Market Cap

159.5M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.42

Market Cap

129.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
SPRO
Founded
1953
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
129.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PLBY
SPRO
Price
$1.59
$2.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$5.00
AVG Volume (30 Days)
363.5K
335.9K
Earning Date
03-12-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,510,000.00
$40,549,000.00
Revenue This Year
$4.97
N/A
Revenue Next Year
$8.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.51
52 Week High
$2.53
$3.22

Technical Indicators

Market Signals
Indicator
PLBY
SPRO
Relative Strength Index (RSI) 31.97 48.11
Support Level $1.47 $2.10
Resistance Level $1.91 $2.49
Average True Range (ATR) 0.08 0.11
MACD -0.03 -0.01
Stochastic Oscillator 5.62 53.85

Price Performance

Historical Comparison
PLBY
SPRO

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: